Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
TRIUMPH-3 (NCT05882045) Design: Phase 3, 80-week, randomised, double-blind, placebo-controlled trial in adults with severe obesity (Class 2 or 3, BMI 35) and established cardiovascular disease, with or without type 2 diabetes
Challenges In Proving Neuroprotective Benefits of GLP-1 Receptor Agonists Demonstrating slowed neurodegeneration requires long-term follow-up and precise measurement tools
"It's the first new drug for function and symptoms in PAD in 25 years, after many attempts to find novel therapies," says study leader Dr
Tracking is not optional
A more biovailable form of berberine
US$ 25.72
US$ 21.30
US$ 20.36
US$ 22.77
US$ 23.52
US$ 27.99
